LEVELS OF PLASMA LIPID PEROXIDE PRODUCTS AND ANTIOXIDANT STATUS IN RHEUMATOID ARTHRITIS

Saowanee Kajanachumpol¹, Monchand Vanichapuntu¹, Oravan Verasertniyom¹, Kitti Totemchokchyakarn² and Mongkol Vatanasuk²

¹Research Center, Faculty of Medicine; ²Division of Allergy, Immunology and Rheumatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand

Abstract. Oxygen free radicals have been implicated as mediators of tissue damage in patients with rheumatoid arthritis. The aim of our study was to assess the lipid peroxide products and antioxidant status in rheumatoid arthritis patients (RA). The study involved determination of two plasma lipid peroxide products, malondialdehyde (MDA) and conjugated dienes (CD), two plasma antioxidant vitamins (C and E) in 91 RA patients and 26 healthy subjects. The results showed that rheumatoid patients had increased plasma CD but not MDA and decreased plasma vitamin E, when properly expressed per unit cholesterol and triglyceride. This finding suggested that RA patients had increased oxidant stress that might play a role in the tissue damage and inflammation process of this disease.

INTRODUTION

Rheumatoid arthritis (RA) is characterized by a chronic hypertrophic synovitis leading to destruction of connective tissues and functional damage of cartilage and bony structure. Reactive oxygen species (ROS) play an important role in tissue injury in this disease (Blake et al, 1989). Several mechanisms exist whereby oxygen radicals might be generated within the joint in RA. These include the release of such species from activated synovial macrophages and polymorphs (Babior, 1978; Halliwell, 1982), the prostaglandin pathway (Egan et al, 1976) and xanthine oxidase mediated synovial ischemic reperfusion injury. The prime targets of ROS attack are the polyunsaturated fatty acids (PUFA) in the membrane lipids causing lipid peroxidation which may lead to disorganization of cell structure and function (Floyd, 1990). Hence, lipid peroxides (LPO) produced from PUFA in the presence of free radicals may reflect the level of free radicals in the body.

To circumvent the damage caused by the ROS, multiple defense systems collectively called "antioxidants" are present in human serum, as well as in erythrocytes.

Patients with rheumatoid arthritis have been reported to have elevate levels of lipid peroxides, which include malondialdehyde in the serum and synovial fluid (Lunec *et al*, 1981; Ozgunes *et al*, 1995; Gambhir *et al*, 1997), and lower levels of antioxidant vitamins A and E in serum in some, but not all studies (Hankanen *et al*, 1989; Bendich and Cohen, 1996). Overwhelming production of free radicals or insufficient antioxidant may play a signifi-

cant role in the tissue-damaging and inflammation perpetuating process in RA (Merry *et al*, 1989). Study of the formation of LPO products and antioxidant status in patients suffering from RA would be an initial step towards elaboration of the oxidant-antioxidant equilibrium among these patients, and for subsequent evaluation of LPO products in relation to the clinical course of the disease with implications for treatment with antioxidants.

MATERIALS AND METHODS

Ninety-one patients, all females aged 21-83 years, were followed at the outpatient Rheumatology clinic of Ramathibodi Hospital. All cases met the revised criteria for rheumatoid arthritis of the American College of Rheumatology. Duration of illness was between 10 months to 33 years. Six of them had inflamed and swollen joints on the day of taking blood. Seropositivity for antinuclear antibodies (titer \geq 1:16) and anti-double stranded-DNA antibodies was found in 45 patients and 1 case respectively. Twenty-six healthy subjects, all females aged 18-68 years, served as controls. Blood samples were drawn from the patients and control subjects with their informed consent.

Hemoglobin (Hb), hematocrit (Hct), white blood cell counts (WBC) and erythrocyte sedimentation rate (ESR) were performed in all patients, except that ESR data were not obtained from 7 patients.

The plasma from ethylene diamine tetraacetic acid anticoagulated blood was separated, immediately stored at -80°C and used for determination of

malondialdehyde (MDA), conjugated dienes (CD), vitamin E (Vit E), vitamin C (Vit C), cholesterol and triglyceride. MDA was determined by its reaction with thiobarbituric acid (TBA) to form a red MDA-TBA complex (Das *et al*, 1990) which was quantitated by fluorometry (Richard *et al*, 1991). CD was measured as relative absorbance at 233 nm wavelength (Beuge and Aust, 1978; Hunter and Mohamed, 1986). Plasma vitamins E and C were determined by a fluorometric method (Taylor *et al*, 1976) and a spectrophotometric method (Omaye *et al*, 1979) respectively while plasma cholesterol and triglyceride were quantitated with a commercial enzymatic kit.

Statistical analysis

All data were expressed as mean \pm SD. Unpaired student's *t*-test was used for between-group comparisons. Differences were considered of statistical significance when the p-value was less than 0.05.

RESULTS

The age, biochemical and hematological data of controls and RA patients are shown in Table 1. The mean ages of RA patients were higher than the controls (RA = 48.8 ± 12.8 years *vs* controls =

40.8±14.5 years). The patient group had significantly lower values of plasma cholesterol, hemoglobin and hematocrit than the control subjects. The WBC counts and ESR values were presented only in RA patients and their ranges were 2.59-13.4 and 1-130 respectively.

Table 2 demonstrates that the RA patients tended to have increased plasma MDA levels compared with controls but it did not reach the statistical significance. The concentrations of CD were markedly increased in the patients. Plasma vitamin E values in RA patients had a tendency to be decreased but they were significantly lower when vitamin E was expressed per millimole of plasma triglyceride plus plasma cholesterol. The concentrations of plasma vitamin C did not differ significantly between the two groups.

DISCUSSION

From all rheumatoid arthritis patients, 33/91 (33%) had low levels of Hb (Hb \leq 11 g%), 41/91 (45%) had low levels of Hct (Hct \leq 36%), 9/91 (10%) had low WBC counts (WBC \leq 4,500 cells/ µl) and 79 of 84 patients (94%) had high ESR (ESR > 20).

$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$
$\begin{array}{cccc} 158 & -290) & (117 & -304) \\ 2.2 \pm 47.8 & 128.4 \pm 81.9 \\ (45 & -196) & (37 & -495) \\ - & 5.84 \pm 2.34 \end{array}$
2.2 ±47.8 128.4 ±81.9 (45 - 196) (37 - 495) - 5.84 ±2.34
(45 - 196) (37 - 495) - 5.84 ±2.34
- 5.84 ±2.34
$(1 \ 2 \ 15 \ 5)$
(1.3 - 15.5)
$11.53 \pm 1.48^{\circ}$
0.5 - 15.2) (6.9 - 15.6)
0.4 ± 3.42 35.6 ± 4.36^{d}
(30-45) (22.6-47.7)
- 7.54±2.66
(2.59 - 13.4)
- 60.6±27.9
•

				Table 1			
The	age,	biochemical	and	hematological	data	of controls	and patients.

a = significant difference from the controls at p < 0.007; b = significant difference from the controls at p < 0.027; c = significant difference from the controls at p < 0.00001; d = significant difference from the controls at p < 0.00001. * WBC = white blood cell, ESR = erythrocyte sedimentation rate; data in parentheses are ranges

Control $(n = 26)$	RA patient $(n = 91)$
1.13±0.26	1.22±0.76
0.45 ± 0.09	0.60 ± 0.25^{a}
1.33±0.27	1.23±0.41
6.60±0.93	6.38±1.41
5.16±0.60	4.75±1.10 ^b
1.18±0.37	1.06±0.39
	$ \begin{array}{c} 1.13 \pm 0.26 \\ 0.45 \pm 0.09 \\ 1.33 \pm 0.27 \\ 6.60 \pm 0.93 \\ 5.16 \pm 0.60 \end{array} $

Table 2 Plasma lipid peroxide and antioxidant levels in the controls and patients.

MDA = malondialdehyde, CD = conjugated dienes

^a = significant difference from the controls at p < 0.00001

 $^{\rm b}$ = significant difference from the controls at p < 0.021

The lipid peroxide (LPO) products, especially MDA, have been established as indicators of lipid peroxidation (Kwon and Watts, 1964). Since MDA is much easier to measure with the thiobarbituric acid method, it is more commonly used in clinical trials, although there is criticism of the specificity of this method. Conjugated dienes, another marker which is an intermediate of lipid peroxidation, were included in this study. The determination of MDA and CD values was used as indicators of lipid peroxidation and also to study its consequence on antioxidant status.

Our results showed that rheumatoid arthritis patients had a tendency to have increased plasma MDA as compared to controls but it did not reach statistical significance. This finding differed from other studies, which found that RA patients with active disease had an increase in the levels of MDA (Ozgunes *et al*, 1995; Gambhir *et al*, 1997). Most of our patients were not in the active stage of disease on the day the blood was drawn . However, the concentrations of CD were significantly increased in the patients. Significantly elevated levels of CD in RA patients were accepted as indirect evidence of increase lipid peroxidation.

Vitamin E, which is an important lipid soluble antioxidant, is transported in serum with serum lipid. Thus the level of plasma vitamin E was expressed per unit plasma lipids. When vitamin E was appropriately expressed per unit cholesterol and triglyceride as suggested by Regnstrom *et al* (1996), its levels in the plasma of RA patients were significantly lower than the controls. This report was confirmed by other studies (Situnayake *et al*, 1991; Comstock *et al*, 1997). The low concentrations of this antioxidant may in some way relate to the development of RA disease, either directly or as an associations with etiologic factors. Heliovaara *et al* (1994) have demonstrated that a low antioxidant level was a risk factor for development of RA disease. It is possible that vitamin E was consumed in the process of counter-balancing the free radicals. A decrease in plasma vitamin E was also observed in juvenile rheumatoid arthritis (Araujo *et al*, 1998). Edmonds *et al* (1997) have reported that treatment with vitamin E in RA patients can not reduce clinical indices of inflammation, but increases analgesic action.

Vitamin C is one of the most efficient water soluble antioxidants. Our finding revealed that the levels of vitamin C in RA patients did not differ from the controls. Situnayake *et al* (1991) have reported a significant decrease in plasma vitamin C levels in RA patients with moderately active inflammatory activity, and 70% of these patients were seropositive for rheumatoid factor. In our study we did not measure the disease activity of the subjects on the day of taking blood.

We concluded that patients with RA presented an imbalance in the oxidant-antioxidant system that markedly increased lipid peroxide products, particularly CD, and significantly decreased lipid soluble antioxidant vitamin E. These changes might play a role in the tissue damage and inflammation process in this disease.

In summary, our data provided preliminary evidence that patients suffering from RA had a significant increase in lipid peroxide products, especially CD, and a significant decrease in antioxidant vitamin E. In the future, mechanisms to decrease the generation of lipid peroxide and/or antioxidant therapy may develop into new avenue of therapeutic intervention.

REFERENCES

Araujo V, Arnal C, Boronat M, Ruiz E, Dominguez C.

Oxidant-antioxidant imbalance in blood of children with juvenile rheumatoid arthritis. *Biofactors* 1998; 8: 155-9.

- Babior BM. Oxygen dependent microbial killing by phagocytes. N Engl J Med 1978; 298: 721-5.
- Bendich A, Cohen M. Vitamin E, rheumatoid arthritis and other arthritis disorders. *J Nutr Immunol* 1996; 4: 47-65.
- Beuge JA, Aust SV. Microsomal lipid peroxidation. *Methods Enzymol* 1978; 52: 302-10.
- Blake DR, Merry P, Unsworth J, *et al*. Hypoxic reperfusion injury in the inflamed human joint. *Lancet* 1989; 1: 289-93.
- Comstock GW, Burke AE, Hoffman SC, *et al.* Serum concentrations of α tocopherol, β carotene and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis* 1997; 56: 323-5.
- Das BS, Thurnham DI, Patnaik JK, Das DB, Statpathy R, Bose TK. Increased plasma lipid peroxidation in riboflavin-deficient, malaria infected children. *Am J Clin Nutr* 1990; 51: 859-63.
- Edmonds SE, Winyard PG, Guo R, *et al.* Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. *Ann Rheum Dis* 1997; 56: 649-55.
- Egan RW, Paxton J, Kuehl FA Jr. Mechanisms for irreversible self deactivation of prostaglandin synthetase. *J Biol Chem* 1976; 251: 7329-35.
- Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. *FASEB J* 1990; 4: 2587-97.
- Gambhir J K, Lali P, Jain AK. Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. *Clin Biochem* 1997; 30: 351-5.
- Halliwell B. Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: A cause of chronic inflammatory disease. *Cell Biol Int Rep* 1982; 6: 529-42.
- Hankanen V, Konttinen YT, Mussalo-Rauhamaa H. Vitamins A and E, retinol binding protein and zinc in

rheumatoid arthritis. Clin Exp Rheumatol 1989; 7: 465-9.

- Heliovaara M, Knekt P, Aho K, Aaran R-N, Alfthan G, Aromaa A. Serum antioxidants and risk of rheumatoid arthritis. *Ann Rheum Dis* 1994; 53: 51-3.
- Hunter MIS, Mohamed JB. Plasma antioxidants and lipid peroxidation products in Duchenne muscular dystrophy. *Clin Chim Acta* 1986; 155: 123-32.
- Kwon TW, Watts BM. Malondialdehyde in aqueous solution and its role as a measure of lipid oxidation in food. *J Food Sci* 1964; 29: 294-302.
- Lunec J, Halloran SP, Whithe AG, Dormandy Tl. Free radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis. *J Rheumatol* 1981; 8: 233-45.
- Merry P, Winyard PG, Morris CJ, Grootveld M, Blake DR. Oxygen free radicals, inflammation and synovitis: the current status. *Ann Rheum Dis* 1989; 48: 864-70.
- Omaye ST, Turnbull D, Sauberlich HE. Selected methods for the determination of ascorbic acid in animal cell, tissue and fluids: Ascorbic acid analysis II. Determination after derivatization with 2,4 dinitrophenyl hydrazine. *Methods Enzymol* 1979; 62: 3-11.
- Ozgunes H, Gurer H, Tuncer S. Correlation between plasma malondialdehyde and ceruloplasmin activity values in rheumatoid arthritis. *Clin Biochem* 1995; 28: 193-4.
- Regnstrom J, Nilsson J, Moldeus P, et al. Inverse relation between the concentration of low-density-lipoprotein vitamin E and severity of coronary artery disease. Am J Clin Nutr 1996; 63; 377-85.
- Richard MJ, Arnaud J, Jurkovitz C, et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. *Nephron* 1991; 57: 10-5.
- Situnayake RD, Thurnham DI, Kootathep S, *et al.* Chain breaking antioxidant status in rheumatoid arthritis: clinical and laboratory correlates. *Ann Rheum Dis* 1991; 50: 81-6.
- Taylor SL, Lamden MP, Tappel AJL. Sensitive fluorometric method for tissue tocopherol analysis. *Lipid* 1976; 11: 530-8.